Whole Exome Sequencing (WES)

Whole Exome Sequencing (WES) is a highly precise genomic technique that utilizes Next-Generation Sequencing (NGS) to simultaneously analyze all protein-coding regions (the exome) of the human genome. Although the exome represents only about 1–2% of the total genome, it contains approximately 85% of all known disease-causing genetic mutations. This makes WES an extraordinarily cost-effective and clinically impactful solution for diagnosing rare and complex genetic disorders.

Key Features & Advantages

1. High Diagnostic Yield: Uncovers the underlying genetic causes of undiagnosed, atypical, or phenotypically complex rare diseases with high diagnostic success rates.
2. Comprehensive Genomic Coverage: Scans approximately 20,000 genes and over 180,000 exons in a single assay, eliminating the need for iterative single-gene testing.
3. Cost and Time Efficiency: Ends the years-long "diagnostic odyssey" for patients by shortening time-to-diagnosis and reducing cumulative healthcare costs.
4. Novel Variant Discovery: Provides a robust platform for identifying known pathogenic mutations as well as novel variants of uncertain significance (VUS) for functional study.

Whole Exome Sequencing (WES) vs. Whole Genome Sequencing (WGS)

Clinical & Research Applications

1. Rare and Undiagnosed Diseases: Resolving unexplained syndromic cases, particularly neurodevelopmental, metabolic, and congenital disorders.
2. Pediatric & Prenatal Genetics: Early-onset condition diagnosis, family planning, and carrier screening.
3. Hereditary Cancer Syndromes: Identifying germline mutations responsible for familial cancer predispositions.
4. Trio Analysis (Proband + Parents): Filtering de novo mutations and confirming inheritance patterns (autosomal dominant/recessive).

The Nucleus Genetics Advantage: Powered by high-depth NGS platforms, internationally validated clinical bioinformatics pipelines, and an expert medical genetics team, we translate complex genomic variants into clear, actionable clinical reports.